Overexpression of HER2/HER3 and clinical feature of ovarian cancer

Ye Won Chung, Seongmin Kim, Jin Hwa Hong, Jae Kwan Lee, Nak Woo Lee, Young Seok Lee, Jae Yun Song

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3 expression levels in specimens of epithelial ovarian cancer and determined their correlation with clinical features of ovarian cancer. Methods: Tissue microarrays (TMAs) were prepared from paraffin blocks of 105 ovarian tumour samples. HER2, HER3, PI3K, Akt, p-Akt, mTOR, p-mTOR, S6, and p-S6 expression levels were investigated using immunohistochemistry (IHC). HER2 and HER3 amplifications were determined using in situ hybridization (ISH). The correlation between HER2/3 expression and disease outcome of the patients including surgical outcome, progression-free survival (PFS) and overall survival (OS) was analysed. Results: HER2 positivity was 3.8% by IHC and 5.7% by ISH, whereas that of HER3 was 12.4% and 8.6%, respectively. HER2 status by either IHC or ISH was not related to PFS (p=0.128, 0.168, respectively) and OS (p=0.245, 0.164, respectively). However, the HER3 status determined using fluorescence ISH was associated with poor PFS (p=0.035 on log rank test), which was a significant risk factor even after adjusting other possible risk factors in multivariate analysis (hazard ratio=2.377 [1.18–7.49], p=0.021). Expressions of Akt, p-mTOR, and S6 were also related with poor progression (p=0.008, 0.049, 0.014, respectively). Conclusion: HER3 is possibly an independent marker for poor prognosis in individuals with ovarian cancer, as the HER3 signalling pathway is distinct from that of HER2. The possibility of targeted therapy for patients with HER3 alteration in ovarian cancer should be evaluated.

Original languageEnglish
Article numbere75
JournalJournal of gynecologic oncology
Volume30
Issue number5
DOIs
Publication statusPublished - 2019 Sep

Fingerprint

Ovarian Neoplasms
S 6
Disease-Free Survival
In Situ Hybridization
Immunohistochemistry
Survival
human ERBB2 protein
Receptor Protein-Tyrosine Kinases
Fluorescence In Situ Hybridization
Phosphatidylinositol 3-Kinases
Epidermal Growth Factor Receptor
Paraffin
Multivariate Analysis
Neoplasms

Keywords

  • Immunohistochemistry
  • In Situ Hybridization
  • Ovarian Cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Overexpression of HER2/HER3 and clinical feature of ovarian cancer. / Chung, Ye Won; Kim, Seongmin; Hong, Jin Hwa; Lee, Jae Kwan; Lee, Nak Woo; Lee, Young Seok; Song, Jae Yun.

In: Journal of gynecologic oncology, Vol. 30, No. 5, e75, 09.2019.

Research output: Contribution to journalArticle

@article{e44cc926e17841fd958054889648ad13,
title = "Overexpression of HER2/HER3 and clinical feature of ovarian cancer",
abstract = "Objectives: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3 expression levels in specimens of epithelial ovarian cancer and determined their correlation with clinical features of ovarian cancer. Methods: Tissue microarrays (TMAs) were prepared from paraffin blocks of 105 ovarian tumour samples. HER2, HER3, PI3K, Akt, p-Akt, mTOR, p-mTOR, S6, and p-S6 expression levels were investigated using immunohistochemistry (IHC). HER2 and HER3 amplifications were determined using in situ hybridization (ISH). The correlation between HER2/3 expression and disease outcome of the patients including surgical outcome, progression-free survival (PFS) and overall survival (OS) was analysed. Results: HER2 positivity was 3.8{\%} by IHC and 5.7{\%} by ISH, whereas that of HER3 was 12.4{\%} and 8.6{\%}, respectively. HER2 status by either IHC or ISH was not related to PFS (p=0.128, 0.168, respectively) and OS (p=0.245, 0.164, respectively). However, the HER3 status determined using fluorescence ISH was associated with poor PFS (p=0.035 on log rank test), which was a significant risk factor even after adjusting other possible risk factors in multivariate analysis (hazard ratio=2.377 [1.18–7.49], p=0.021). Expressions of Akt, p-mTOR, and S6 were also related with poor progression (p=0.008, 0.049, 0.014, respectively). Conclusion: HER3 is possibly an independent marker for poor prognosis in individuals with ovarian cancer, as the HER3 signalling pathway is distinct from that of HER2. The possibility of targeted therapy for patients with HER3 alteration in ovarian cancer should be evaluated.",
keywords = "Immunohistochemistry, In Situ Hybridization, Ovarian Cancer",
author = "Chung, {Ye Won} and Seongmin Kim and Hong, {Jin Hwa} and Lee, {Jae Kwan} and Lee, {Nak Woo} and Lee, {Young Seok} and Song, {Jae Yun}",
year = "2019",
month = "9",
doi = "10.3802/jgo.2019.30.e75",
language = "English",
volume = "30",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "5",

}

TY - JOUR

T1 - Overexpression of HER2/HER3 and clinical feature of ovarian cancer

AU - Chung, Ye Won

AU - Kim, Seongmin

AU - Hong, Jin Hwa

AU - Lee, Jae Kwan

AU - Lee, Nak Woo

AU - Lee, Young Seok

AU - Song, Jae Yun

PY - 2019/9

Y1 - 2019/9

N2 - Objectives: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3 expression levels in specimens of epithelial ovarian cancer and determined their correlation with clinical features of ovarian cancer. Methods: Tissue microarrays (TMAs) were prepared from paraffin blocks of 105 ovarian tumour samples. HER2, HER3, PI3K, Akt, p-Akt, mTOR, p-mTOR, S6, and p-S6 expression levels were investigated using immunohistochemistry (IHC). HER2 and HER3 amplifications were determined using in situ hybridization (ISH). The correlation between HER2/3 expression and disease outcome of the patients including surgical outcome, progression-free survival (PFS) and overall survival (OS) was analysed. Results: HER2 positivity was 3.8% by IHC and 5.7% by ISH, whereas that of HER3 was 12.4% and 8.6%, respectively. HER2 status by either IHC or ISH was not related to PFS (p=0.128, 0.168, respectively) and OS (p=0.245, 0.164, respectively). However, the HER3 status determined using fluorescence ISH was associated with poor PFS (p=0.035 on log rank test), which was a significant risk factor even after adjusting other possible risk factors in multivariate analysis (hazard ratio=2.377 [1.18–7.49], p=0.021). Expressions of Akt, p-mTOR, and S6 were also related with poor progression (p=0.008, 0.049, 0.014, respectively). Conclusion: HER3 is possibly an independent marker for poor prognosis in individuals with ovarian cancer, as the HER3 signalling pathway is distinct from that of HER2. The possibility of targeted therapy for patients with HER3 alteration in ovarian cancer should be evaluated.

AB - Objectives: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3 expression levels in specimens of epithelial ovarian cancer and determined their correlation with clinical features of ovarian cancer. Methods: Tissue microarrays (TMAs) were prepared from paraffin blocks of 105 ovarian tumour samples. HER2, HER3, PI3K, Akt, p-Akt, mTOR, p-mTOR, S6, and p-S6 expression levels were investigated using immunohistochemistry (IHC). HER2 and HER3 amplifications were determined using in situ hybridization (ISH). The correlation between HER2/3 expression and disease outcome of the patients including surgical outcome, progression-free survival (PFS) and overall survival (OS) was analysed. Results: HER2 positivity was 3.8% by IHC and 5.7% by ISH, whereas that of HER3 was 12.4% and 8.6%, respectively. HER2 status by either IHC or ISH was not related to PFS (p=0.128, 0.168, respectively) and OS (p=0.245, 0.164, respectively). However, the HER3 status determined using fluorescence ISH was associated with poor PFS (p=0.035 on log rank test), which was a significant risk factor even after adjusting other possible risk factors in multivariate analysis (hazard ratio=2.377 [1.18–7.49], p=0.021). Expressions of Akt, p-mTOR, and S6 were also related with poor progression (p=0.008, 0.049, 0.014, respectively). Conclusion: HER3 is possibly an independent marker for poor prognosis in individuals with ovarian cancer, as the HER3 signalling pathway is distinct from that of HER2. The possibility of targeted therapy for patients with HER3 alteration in ovarian cancer should be evaluated.

KW - Immunohistochemistry

KW - In Situ Hybridization

KW - Ovarian Cancer

UR - http://www.scopus.com/inward/record.url?scp=85073283465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073283465&partnerID=8YFLogxK

U2 - 10.3802/jgo.2019.30.e75

DO - 10.3802/jgo.2019.30.e75

M3 - Article

C2 - 31328457

AN - SCOPUS:85073283465

VL - 30

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 5

M1 - e75

ER -